ReviewHigh blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension2022
Hypertension and COVID-19: Current Evidence and Perspectives.
Review in High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 2 syntheses or guidelines pooled it, 130 citations in OpenAlex.
- Clinical and immunological comparison of COVID-19 disease between critical and non-critical courses: a systematic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- Organokines in COVID-19: A Systematic Review.Cells · 2023Pooled it
- The impact of COVID-19 on mortality among diabetic and hypertensive individuals in coastal communities in Bangladesh: evidence from chakaria health and demographic surveillance system.Population health metrics · 2026Article
- Risk factors and outcomes of secondary co-infections in hospitalised COVID-19 patients in Malaysia: a case control study.BMC microbiology · 2026Article
- Baseline cohort profile: clinical and molecular characterisation of SARS-CoV-2 infected patients recruited into a longitudinal COVID-19 cohort study (COVGEN) in Malaysia.BMC infectious diseases · 2026Article
- An Ecological Study on the Mortality Impact of the COVID-19 Pandemic According to Country Development Status and Pandemic Years.Epidemiologia (Basel, Switzerland) · 2026Article
- Impact of in-hospital SARS-CoV-2 infection on mortality and outcomes in patients admitted for heart failure: a nationwide analysis in Brazil.Frontiers in cardiovascular medicine · 2026Article
- Risk assessment for cardiovascular adverse drug events in the ICU: Case study on COVID-19 patients.PloS one · 2026Article
- Adverse drug events in hospitalized COVID-19 patients: a pharmacovigilance perspective on ICU management and fentanyl exposure.Frontiers in epidemiology · 2026Article
- Evaluation of glucose metabolism, endocrine, and renal functions following vaccination in post-COVID-19 individuals: a longitudinal retrospective single-center cohort study.BMC infectious diseases · 2025Article
- Pericardial Fat Tissue as a Predictor of the Severity of Acute Coronavirus Infection COVID-19.Journal of clinical medicine research · 2025Article
- COVID-19 as the occupational disease in employees of the University Hospital Ostrava.Central European journal of public health · 2025Article
- Neurocognitive Impairment After COVID-19: Mechanisms, Phenotypes, and Links to Alzheimer's Disease.Brain sciences · 2025Review
- The Involvement and Manifestations of SARS-CoV-2 Virus in Cardiovascular Pathology.Medicina (Kaunas, Lithuania) · 2025Review
- Development and validation of a highly sensitive HPLC method for quantifying cardiovascular drugs in human plasma using dual detection.Scientific reports · 2025Article
- Omics for searching plasma biomarkers associated with unfavorable COVID-19 progression in hypertensive patients.Scientific reports · 2025Article
- The Distribution of Sport Performance Gene Variations Through COVID-19 Disease Severity.Diagnostics (Basel, Switzerland) · 2025Article
- Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection.Nature medicine · 2025Article
- Article
- Beneficial Effects of Angiotensin II Receptor Blockers on Mortality in Patients with COVID-19: A Retrospective Study from 2019 to 2020 in China.Cardiovascular drugs and therapy · 2025Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) outbreak, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), represents a real challenge for health-care systems worldwide. Male sex, older age and the coexistence of chronic comorbidities have been described as the most relevant conditions associated with a worse prognosis. Early reports suggested that hypertension might represent a risk factor for susceptibility to SARS-CoV-2 infection, a more severe course of COVID-19 and increased COVID-19-related deaths. Nevertheless, the independent role of hypertension remains under debate, since hypertension is often associated with the older age and other cardiovascular (CV) risk factors in the general population, which may also contribute to the SARS-Cov-2 infection and COVID-19. Moreover, the role of antihypertensive drugs, primarily angiotensin-converting inhibitors (ACEIs) and ARBs (angiotensin receptor blockers) in COVID-19 development and outcome appears controversial. Indeed, preclinical studies using these classes of drugs have suggested a potential upregulation of angiotensin-converting-enzyme 2 (ACE2) which is the key binding receptor promoting cell entry of SARS-CoV-2 in the organism. Renin-angiotensin system (RAS) blockers may potentially upregulate ACE2, hence, it has been initially hypothesized that these agents might contribute to a higher risk of SARS-CoV-2 infection and progressive course of COVID-19. However, several clinical reports do not support a detrimental role of RAS blockers in COVID-19, and an intense debate about the withdrawal or maintenance of chronic therapy with ACEi/ARB has been developed. In this review we will discuss the available evidence on the role of hypertension and antihypertensive drugs on SARS-CoV-2 infection and COVID-19 development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.